| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/10/2005 | US20050032764 oximation of d-norgestrel to form d-(17 alpha )-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3E- and -3Z-oxime isomers, used as contraceptives; hormone replacement therapy |
| 02/10/2005 | US20050032763 Process for the synthesis of high purity D-(17a)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one oxime |
| 02/10/2005 | US20050032762 injectable formulations comprising mixtures of testosterone ester such as testosterone undecanoate, in vehicles comprising castor oils and cosolvents; hormone replacement therapy and male contraception |
| 02/10/2005 | US20050032761 Lipid profile modulation |
| 02/10/2005 | US20050032760 Continuous process for the production of r-rofleponide |
| 02/10/2005 | US20050032759 administering to humans synergystic mixtures of aromatase inhibitors and epidermal growth factor receptor antagonists as antitumor agents |
| 02/10/2005 | US20050032758 Hormone replacement therapy and depression |
| 02/10/2005 | US20050032757 Nutritional supplements |
| 02/10/2005 | US20050032756 mixture of estradiol valerate and dienogest or drospirenone; hormones having side effect reduction |
| 02/10/2005 | US20050032755 Dosage regimen and pharmaceutical composition for emergency contraception |
| 02/10/2005 | US20050032754 the 2-position is substituted, the steric configuration at the 20-position is native or epimerized, and the double bond at the 5-position is in E configuration; calcium metabolism regulating agent; does not cause hypercalcemia during long-term use |
| 02/10/2005 | US20050032753 Substituted phenol compounds useful for anesthesia and sedation |
| 02/10/2005 | US20050032751 Methods for treatment of dermatological conditions |
| 02/10/2005 | US20050032750 Treating androgen deficiency in female (ADIF)-associated conditions with SARMS |
| 02/10/2005 | US20050032749 Pamidronate solution |
| 02/10/2005 | US20050032748 Substituted 2,5-dioxopurines, 2H-1,2,3-triazolyl[4,5-d]pyrimidines, or 1,2,5-thadiazolyl[3,4-d]pyrimidines; antiproliferative, antiinflammatory, and antiarthritic agents; psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, lupus, graft versus host disease |
| 02/10/2005 | US20050032747 Cyclooxygenase-2 and Fatty Acid Amide Hydrolase; substituted N-benzoyl-5-((alkyl carbonyl, alkyloxycarbonyl, alkylaminocarbonyl or alkylphosphonato)oxy)indoles; analgesics, antiinflammatory and anxiolytic agents |
| 02/10/2005 | US20050032746 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 02/10/2005 | US20050032745 Modified low molecular weight heparin that inhibits clot associated coagulation factors |
| 02/10/2005 | US20050032744 Method for alleviating pain using sphingosine-1-phosphate and related compounds, and assays for identifying such compounds |
| 02/10/2005 | US20050032743 A sugar-boron complex and calcium, magnesium, or vitamin D; prevention or treatment of bone density loss |
| 02/10/2005 | US20050032742 Chemo-enzymatic synthesis of sialylated oligosaccharides |
| 02/10/2005 | US20050032741 Vitamin Compositions |
| 02/10/2005 | US20050032740 Vitamin B12, vitamin B6, folic acid, magnesium, and vitamin E; anticholesterol agents |
| 02/10/2005 | US20050032739 Topical antiviral therapeutic and prophylactic treatment of adenoviruses and their associated diseases |
| 02/10/2005 | US20050032738 (E)-2'-deoxy-2'-fluoromethylidenecytidine, cytidine, vinblastine, or fluorouracil; leukemia |
| 02/10/2005 | US20050032736 Immunostimulatory nucleic acid molecules |
| 02/10/2005 | US20050032724 Multidrug Resistance Protein 1 (MRP1); mutagenesis |
| 02/10/2005 | US20050032723 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 02/10/2005 | US20050032721 Methods of administering dalbavancin for treatment of skin and soft tissue infections |
| 02/10/2005 | US20050032720 contains misoprostol, a tetracycline (doxycycline), an aminoglycoside (gentamicin), a fluoroquinoline (ciprofloxacin), a lincomycin (clindamycin), a macrolide (clarithromycin), an azalide (azithromycin), and an imidazole (metronidazole) |
| 02/10/2005 | US20050032719 Anthelmintic formulations |
| 02/10/2005 | US20050032718 contain ivermectin plus hexahydropyrazinoisoquinolines (praziquantel ) and tetrahydropyrimidines (pyrantel); treating tapeworm, hookworm, roundworm and heartworm of domestic animals |
| 02/10/2005 | US20050032716 controlling or eradicating Phthiraptera, Siphonaptera and Acarina Pests on domestic animals; contains a synergistic combination of a A83543 compound and a macrocyclic lactone |
| 02/10/2005 | US20050032715 Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| 02/10/2005 | US20050032714 immunotherapeutic for therapy and prophylaxis of cancer; reduced duration, less toxicity, and as thus results in improved tolerance |
| 02/10/2005 | US20050032713 Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents |
| 02/10/2005 | US20050032712 Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides |
| 02/10/2005 | US20050032711 Antidiabetic agents; insulin resistance |
| 02/10/2005 | US20050032710 Alternative agent with vitamin D-like activity and an improving agent for intestinal function |
| 02/10/2005 | US20050032708 up-regulating glutathione metabolism in the central nervous system by up-regulating levels of glutathione precursors (N-acetyl cysteine); for treating neuropsychiatric disorder like schizophrenia, psychosis, bipolar disorder, manic depression, affective disorder, drug induced psychosis, delirium |
| 02/10/2005 | US20050032699 Composition of a VEGF antagonist and an anti-proliferative agent |
| 02/10/2005 | US20050032693 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 02/10/2005 | US20050032692 Methods of inhibiting tumor cell proliferation |
| 02/10/2005 | US20050032691 Methods for treating glaucoma |
| 02/10/2005 | US20050032675 Galectin inhibitors such as fetuin; competitive binding; glycoproteins |
| 02/10/2005 | US20050032674 SAIF, an anti-inflammatory factor, and methods of use thereof |
| 02/10/2005 | US20050032168 17 human secreted proteins |
| 02/10/2005 | US20050032135 Screening for conjugates or agents that are actively transported by MCT1 and MCT4, which are expressed at higher levels in cancer cells; 3-bis(2-chloroethyl)amino-4-methoxybenzoic acid or bis(2-chloroethyl)aminoxyacetic acid for example; use in treatment or diagnosis of cancer |
| 02/10/2005 | US20050032111 Using intregral membrane protein concentration as diagnostic and/or prognostic indicator of successful pregnancy; in vitro fertilization and reproductive disorders |
| 02/10/2005 | US20050032096 Using variations in gene expression profiles of hypertensive patient to determine efficacy of hypotensive agents |
| 02/10/2005 | US20050032068 Oligomers hybridize with each other, one of which includes peptide nucleic acid or mimic, a morpholino nucleic acid, hexose sugar with amide linkage, cyclohexenyl nucleic acid or an acyclic backbone modification; gene expression inhibition |
| 02/10/2005 | US20050032067 Nucleosides; RNA-induced silencing complex; RNA interference; gene expression inhibition |
| 02/10/2005 | US20050032039 HIV-specific T-cell induction |
| 02/10/2005 | US20050032007 comprises water, dispersion medium containing modified gelatin, and spectrally sensitized silver halide grains having multilayer adsorption of dye chromophores on the surface; photosensitive material of high film speed/improved storage stability |
| 02/10/2005 | US20050031772 Ginger extract preparation |
| 02/10/2005 | US20050031737 Mixture of quercetin, vitamins, catechin and caffeine; sexual disorders; inflammatory bowel disorders |
| 02/10/2005 | US20050031717 Salt taste modification |
| 02/10/2005 | US20050031716 Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer |
| 02/10/2005 | US20050031713 Methods for administering active agents to CYP3A4 sensitive patients |
| 02/10/2005 | US20050031709 Butyrospermum-triterpene fraction containing lupeol; alpha -amyrin and/or beta amyrin, and butyrospermol; plant extract |
| 02/10/2005 | US20050031708 Composition comprising a zeolite compound for treatment of diseases |
| 02/10/2005 | US20050031706 A bismuth containing agent , a non-clay-derived suspending agent; an stabilizer for reducing viscosity change during storage of the formulation and water |
| 02/10/2005 | US20050031705 Topical veterinary compositions and methods for the treatment and prevention of infection |
| 02/10/2005 | US20050031700 In the form of a powder for suspension containing (a) an acid-labile proton pump inhibitor in micronized from; b) an antacid; and c) a gum as suspending agent |
| 02/10/2005 | US20050031697 Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| 02/10/2005 | US20050031696 Oral pharmaceutical formulations of acid-labile active ingredients and process for making same |
| 02/10/2005 | US20050031695 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| 02/10/2005 | US20050031692 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
| 02/10/2005 | US20050031691 Gel stabilized nanoparticulate active agent compositions |
| 02/10/2005 | US20050031688 Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration |
| 02/10/2005 | US20050031687 Enteric-coated proliposomal formulations for poorly water soluble drugs |
| 02/10/2005 | US20050031685 Pharmaceutical composition for controlled release of a beta-lactam antibiotic |
| 02/10/2005 | US20050031683 Tablets containing an 8-alkoxyquinolonecarboxylic acid (gatifloxacin, moxifloxacin) antibacterial drug; mixing the drug with polyethylene glycol, adding an excipient comprising a diluent, a disintegrant, a glidant, or a lubricant and compressing the mixture into a tablet |
| 02/10/2005 | US20050031681 Mixture with a thixotropic gelatine carrier to form gelatin capsules; enhanced the solubility, stability and absorption |
| 02/10/2005 | US20050031680 In vivo use of water absorbent polymers |
| 02/10/2005 | US20050031679 Method for producing liposomal formulations of active ingredients |
| 02/10/2005 | US20050031677 Sequential drug delivery systems |
| 02/10/2005 | US20050031675 Water soluble polymer such as pullulan and an antimicrobial effective amount of thymol, methyl salicylate, eucalyptol and/or menthol; killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath |
| 02/10/2005 | US20050031670 hunger-abating, low-calorie, and/or high energy edible composition comprising a bupropion compound and a food component |
| 02/10/2005 | US20050031668 biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time; Parkinson's disease; erectile dysfunction and restless leg syndrome |
| 02/10/2005 | US20050031667 Implantable polymeric device for sustained release of dopamine agonist |
| 02/10/2005 | US20050031665 Orthopedic hardware with a sustained release device configured to release a compound over an extended period of time and is attachable to a portion of the body |
| 02/10/2005 | US20050031654 Composition based on diosgenin ester for topical use |
| 02/10/2005 | US20050031652 Compositions and methods comprising memantine and polyanionic polymers |
| 02/10/2005 | US20050031627 Methods for preparing immunoconjugates |
| 02/10/2005 | US20050031616 Controlled platelet activation to monitor therapy of ADP antagonists |
| 02/10/2005 | US20050031611 Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis |
| 02/10/2005 | US20050031606 Lyase treatment for P. carinii |
| 02/10/2005 | US20050031601 Composition comprising a lactobacillus pentosus strain and uses thereof |
| 02/10/2005 | US20050031600 Cardiac function by mesenchymal stem cell transplantation |
| 02/10/2005 | US20050031597 Cells and improved method for preserving cells |
| 02/10/2005 | US20050031596 Cells and method for preserving cells |
| 02/10/2005 | US20050031589 Method of treating hepatitis C infection |
| 02/10/2005 | US20050031588 2'-branched nucleosides and Flaviviridae mutation |
| 02/10/2005 | US20050031586 Method for treating hepatitis c virus infection in treatment failure patients |
| 02/10/2005 | US20050031585 Treating individuals having hepatitis C virus infection, who have failed to respond to therapy with IFN-alpha other than consensus interferon (CIFN), or who, following cessation of therapy with IFN-alpha other than CIFN, have suffered relapse by administering first, then second dosing CIFN, and ribavirin |
| 02/10/2005 | US20050031578 Comprising a naturally occurring polyol and a biocompatible, synthetic polyol and isocyanate which react to form a polyesterurethane; composition promotes bone growth when positioned in the vicinity of a bone of a mammal |
| 02/10/2005 | US20050031575 Block copolymers |
| 02/10/2005 | US20050031557 Aging resistance from exposure to sun; nontoxic, easy to handle |